Mg5-Longoral

Quick links

Choose a section

Quick links to important sections

Advertisements

Mg5-Longoral

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Mg5-Longoral

Property Description
Active ingredient Magnesium DL-hydrogenaspartate tetrahydrate (Magnesium aspartate)
Form Extended-release tablets (Longoral)
Pharmacological class Mineral supplement, Electrolyte replacement agent
Common use Addressing documented magnesium deficiency (hypomagnesemia)
Origin Synthetically derived mineral salt complex

What Type of Medicine is Mg5-Longoral?

Mg5-Longoral is a specialized pharmaceutical preparation classified as a mineral supplement and an electrolyte replacement agent. It is designed to address and prevent states of magnesium deficiency (hypomagnesemia) and ensure the maintenance of essential electrolyte balance within the body. Magnesium is recognized as an essential mineral, functioning as a cofactor in hundreds of enzyme systems crucial for health. The preparation is clinically recognized for its intended use in situations demanding the restoration of magnesium levels, such as supporting the body during periods of increased metabolic demand. The product is often positioned for patients experiencing chronic or recurrent magnesium deficits.


Composition and Form: Magnesium Aspartate and the Longoral System

The active ingredient in Mg5-Longoral is Magnesium DL-hydrogenaspartate tetrahydrate, also known as magnesium aspartate, delivered in an extended-release tablet form. This ingredient is a synthetically derived magnesium salt where the mineral is chelated with aspartic acid, which acts as a carrier molecule to promote superior absorption into the bloodstream compared to inorganic magnesium salts. Organic magnesium salts, such as aspartate, exhibit higher bioavailability, making them potentially more effective for increasing serum magnesium concentration. A key differentiating feature of this preparation is its monocomponent focus on this specific high-bioavailability salt, distinct from combination mineral products.


General Benefit of its Sustained-Release Design

The 'Longoral' design signifies an extended-release mechanism engineered to ensure the active ingredient is released slowly and continuously over time. This sustained-release formulation is a crucial benefit because it facilitates steady absorption kinetics, minimizing the chance of rapid intestinal saturation and maximizing the total amount of magnesium absorbed by the body. This approach is intended to help maintain stable magnesium levels over a prolonged period. By providing this consistent, prolonged supply, the preparation aims to maintain systemic stability, effectively supporting healthy muscle contraction and optimal nerve impulse transmission.

Regulatory References

  1. National Institutes of Health (NIH)
Advertisements

What side effects are possible with Mg5-Longoral?

Possible side effects and safety information

The safety profile for this magnesium aspartate preparation is defined by adverse reactions primarily affecting the gastrointestinal system and by the risk of hypermagnesemia (magnesium intoxication), particularly in specific patient groups.

Officially Documented Adverse Reactions

The most frequently documented side effects are categorized by regulatory authorities based on their occurrence rate:

  • Uncommon (ge 1/1,000 to < 1/100): Includes soft stools and diarrhoea, which are generally related to the gastrointestinal system.
  • Very Rare (< 1/10,000): May include fatigue or tiredness, which can be associated with long-term exposure.
  • Frequency Not Defined: Other gastrointestinal effects, such as nausea, cramps, and gas formation, have been reported.

Serious Safety Characteristics

The most serious safety risk is hypermagnesemia, or the accumulation of too much magnesium in the body, typically only arising in cases of impaired renal function. The documented signs of severe intoxication include hypotension (low blood pressure), depressed reflexes, respiratory depression, muscle paralysis, and cardiac arrest. These reactions affect the cardiac and nervous system organ classes.

Population-Specific Safety Constraints

Official regulatory documents establish strict constraints for specific populations. The medicine is contraindicated in individuals with severe renal impairment (kidney disease) because the kidneys are essential for eliminating magnesium, and compromised function leads to a high risk of hypermagnesemia. It is also contraindicated in patients with certain cardiac conduction disorders (such as atrioventricular block or bradycardia). Use during pregnancy and lactation is generally considered acceptable if a clinical need is documented.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Mg5-Longoral overdose results in hypermagnesemia, leading to documented effects on the neuromuscular, cardiovascular, and central nervous systems, as stated in official regulatory documents. Early clinical signs of toxicity include nausea, vomiting, flushing, and hypotension. Key manifestations progress to lethargy, confusion, profound muscle weakness, slurred speech, and a depression of deep tendon reflexes, notably the loss of the patellar reflex.


Required Emergency Action

Immediate medical attention must be sought upon the appearance of any documented sign of hypermagnesemia. Severe, life-threatening outcomes described in regulatory documents include respiratory depression, respiratory paralysis, circulatory collapse, heart block, and cardiac arrest. Emergency services must be contacted immediately if any of these severe manifestations are suspected.


Supportive Management and Monitoring

Management involves the immediate discontinuation of magnesium intake. Regulatory materials confirm that injectable calcium salts are used to temporarily counteract acute cardiorespiratory depression. Supportive measures required include enhancing magnesium clearance through forced diuresis or, in cases of severe toxicity or renal impairment, dialysis. Continuous hospital monitoring of serum magnesium levels, reflexes, and ECG is required. Patients with impaired renal function and the elderly are noted to have an increased risk of severe toxicity.

Advertisements

Therapeutic Uses of Mg5-Longoral

Mg5-Longoral is a mineral supplement relevant for managing conditions and symptoms that may be associated with documented magnesium deficiency (hypomagnesemia). The use is relevant for addressing symptoms related to systemic imbalance, contributing to easing the overall symptom load. This therapeutic approach is commonly used across domains where additional symptomatic support is needed to address the systemic imbalance.

It is applied in addressing generalized fatigue, weakness, and lethargy, and may help maintain a sense of stability when symptoms interfere with daily functioning. This includes symptoms of increased neurological or muscular activity, such as painful muscle cramps, spasms, and involuntary twitching, and supportive use in high-risk clinical contexts like deficiency-linked migraine headaches or certain cardiovascular rhythm disturbances.

“The preparation supports the easing of symptoms related to physical discomfort, which may assist with maintaining functional stability.”

Quick Fact: Supportive Relief for Muscle Cramps and Fatigue


Supportive Use in High-Risk Clinical Contexts

Mg5-Longoral is applied in clinical settings marked by the potential for recurrent magnesium loss, such as in patients with Type 2 Diabetes, chronic gastrointestinal issues, or those on certain long-term medications. It is relevant in situations where additional symptomatic support is needed for associated issues, assisting with maintaining functional stability and supporting general well-being.

Regulatory References

  1. NHS Dorset guidance on hypomagnesaemia management
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mg5-Longoral — Official Regulatory Information

The eligibility profile for Mg5-Longoral is strictly defined by regulatory authorities concerning age, physiological status, and underlying health conditions.


Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults and Adolescents (typically 12 years and older).
  • Children aged 2 years and above (with regular monitoring required in some formulations).
  • Pregnant and Lactating Women (Use is permitted when clinically needed, based on available safety data).

Populations for whom use is contraindicated:

  • Severe Renal Impairment (Glomerular Filtration Rate < 30 ml/min).
  • Known Hypersensitivity to the active substance (Magnesium DL-hydrogenaspartate) or excipients.
  • Patients with Myasthenia Gravis or AV Block (a type of heart conduction disorder) in some jurisdictions.

Eligibility-related restrictions:

  • Children Below 2 Years are generally a use-not-established group; safety and efficacy are not confirmed.
  • Mild to Moderate Renal Impairment permits use, but regular monitoring of serum magnesium levels is recommended.
  • Use requires caution for certain individuals with diabetes mellitus or specific hereditary intolerances due to the presence of excipients like sucrose in some formulations.

Connection to the overall eligibility profile

Official regulatory documents strictly define who can and cannot use the medicine by classifying severe organ dysfunction and hypersensitivity as absolute contraindications. Use is generally permitted for adults and during pregnancy/lactation. Restrictions primarily center on ensuring adequate kidney function for magnesium excretion and avoiding use in very young children where safety data is insufficient.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Magnesium aspartate (Mg5-Longoral) has a documented interaction profile primarily structured around reducing the absorption of co-administered medicines and the risk of magnesium accumulation. All listed interactions and restrictions are based solely on official government regulatory documents.


Medicines Requiring Dose Separation (Exposure Reduction)

Medicinal Product Class Official Interaction Outcome
Tetracycline & Quinolone Antibiotics Decreased plasma concentration and efficacy of the antibiotic due to impaired absorption.
Oral Bisphosphonates (e.g., Alendronate, Clodronate) Reduced systemic exposure of the bisphosphonate.
Specific Compounds (e.g., Iron preparations, Fluoride, Penicillamine, Eltrombopag) Impaired absorption or decreased serum concentration.

These interactions are categorized as clinically significant and require administration to be separated by a time interval typically ranging from one to four hours, as specified in regulatory labeling.


Other Documented Interactions

  • Additive Magnesium Load: Co-administration with other magnesium-containing products (such as certain antacids or laxatives) increases the additive risk of hypermagnesemia (magnesium toxicity).
  • Alcohol: Consumption of alcohol is noted to promote the renal excretion of magnesium and inhibit its intestinal absorption.
  • Population Note: The risk of magnesium accumulation is heightened in patients with severe renal dysfunction due to compromised clearance, intensifying the risks associated with an additive magnesium load.
Advertisements

Mechanism of Action

The mechanism of Mg5-Longoral is defined by the fundamental biological role of the magnesium cation ( Mg^2+) as an essential element that modulates and stabilizes cellular bioelectrical and enzymatic activity. The action is one of modulation and regulation, primarily occurring within the nervous, muscular, and vascular systems.

Supporting Cellular Energy and Bioelectrical Potential

The Mg^2+ cation is critical for forming the active Mg-ATP complex, the substrate required to power hundreds of cellular energy-dependent enzymes. Most notably, Mg^2+ activates the Na^+/ K^+-ATPase pump, which maintains the correct electrical gradient across cell membranes. By optimizing the function of this pump, the drug's mechanism leads to a reduction in the intrinsic hyperexcitability of both nerve and muscle cells, supporting the electrical stability of cells.

Modulating Neuromuscular and Smooth Muscle Excitability

The mechanism acts as a functional Ca^2+ antagonist by limiting Ca^2+ entry into excitable cells via voltage-gated channels and suppressing the release of stimulating neurotransmitters like acetylcholine at the neuromuscular junction. This dual action dampens excessive signaling, resulting in the promotion of relaxation in skeletal muscles and smooth muscles, including those that regulate vascular tone. This effect profile results in the modulation of involuntary muscle activity.

Advertisements

Dosage and Administration Information

How to Use Mg5-Longoral

Mg5-Longoral is a specialized preparation used solely via the oral route to address documented magnesium deficiency. Its usage follows a standardized method, frequency, and dosing adjustment protocol.


Official Administration Guidelines

Administration Scope Procedural Instructions
Dosage Form and Integrity The medicine is an extended-release tablet that must be swallowed whole with liquid. It should not be crushed, broken, or chewed, as this compromises the sustained-release mechanism.
Standard Adult Regimen The typical daily dose is one to three tablets, administered in divided doses. The specific dose is determined by the severity of the patient's magnesium deficiency.
Timing and Frequency The daily dosage is usually scheduled one to three times daily and is typically instructed to be taken before meals.

Population and Contextual Rules

Official instructions detail high-level dosing for specific patient groups. Children aged 6 years and older are approved for a reduced dosage, typically starting at a half tablet, administered up to three times per day. The preparation is contraindicated in severe renal impairment due to the risk of magnesium accumulation. The course of treatment is typically long-term, lasting more than four weeks, and continues until the deficiency is fully corrected.

Furthermore, to prevent reduced effectiveness, an interval of at least 1 to 3 hours must separate the dose of Mg5-Longoral from the intake of certain other oral medications, such as iron, fluorides, or tetracyclines.

Advertisements

Recent Clinical Evidence

Evidence for Addressing Documented Magnesium Deficiency (Hypomagnesemia)

Research primarily focuses on the absorption characteristics of the magnesium aspartate salt in its extended-release form. Bioavailability studies and pharmacokinetic evaluations examined how long magnesium remains at stable levels in the bloodstream. Serum magnesium concentration is the key biomarker studied, but evidence for long-term deficiency correction relies largely on these short-term measurements, with data describing sustained stability over many months remaining limited.


Studies on Supportive Management of Related Symptoms

Randomized Controlled Trials (RCTs) have been conducted to explore the supportive role of the preparation in managing symptoms associated with systemic imbalance, such as fatigue, muscle cramps, and overall symptom load. Findings vary across trials, and the existing body of evidence is marked by heterogeneity, indicating that certainty for the durability of the supportive effect is still emerging.


Research in High-Risk Clinical Contexts and Comorbidities

Research has also explored the preparation's use in specific patient groups, including those with Type 2 Diabetes, chronic gastrointestinal issues, or deficiency-linked migraine headaches. The evidence for these subgroups is typically limited, often relying on smaller observational studies where certainty remains low.


Durability and Long-Term Follow-up Data

Follow-up durations were limited in many of the main clinical studies. Long-term outcomes for symptomatic relief are not fully established, and there is limited information describing the sustained maintenance of functional stability beyond the defined study intervals.


Evidence in Specific Patient Subgroups

Data for certain groups, such as children, remain insufficient. Information regarding outcomes in specific severity strata is often integrated into broader trial data, making subgroup findings uncertain. The results apply only to the populations studied.


Key Uncertainties and Research Gaps

A primary research gap is the lack of comparative evidence against all other forms of magnesium supplements available. The evidence quality varies across studies, leading to some uncertainty in synthesizing the overall findings, and continued research is ongoing.

Key Studies & References

  1. Comparative bioavailability of magnesium salts in a human study (Journal of Nutrition and Metabolism)
  2. Management of Hypomagnesaemia in Primary Care Guidance (NHS Dorset)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Mg5-Longoral (FAQ)

Q: Is Mg5-Longoral intended for short-term use or long-term management of a condition?

A: According to official guidelines, Mg5-Longoral is typically intended for long-term management of a deficiency. The usual course of treatment lasts for more than four weeks, and the continuation of therapy is guided by the correction of the magnesium deficiency.


Q: How long does it usually take for a person to notice the effects of Mg5-Longoral?

A: Official documentation focuses on the stability of magnesium levels in the bloodstream, known as serum concentration, as the key measure of effect. Because individual factors influence how a person responds to treatment, official documents do not provide a fixed timeline for when subjective relief from symptoms may be noticed.


Q: What are patients typically told to expect after starting a course of Mg5-Longoral?

A: The medicine is designed to support the basic electrical stability of nerve and muscle cells throughout the body. Its mechanism works to reduce the excessive signaling, or hyperexcitability, that can occur during deficiency, which is linked to promoting relaxation in skeletal and smooth muscles.


Q: What is the proper description of the risk of too much magnesium while on Mg5-Longoral?

A: The most serious safety concern is the risk of hypermagnesemia, which is a condition where there is too much magnesium in the body. This is typically only a high risk for patients with compromised kidney function. Documented signs of severe hypermagnesemia include low blood pressure (hypotension), depressed reflexes, difficulty breathing, and can ultimately lead to cardiac arrest.


Q: Is there a known interaction risk between Mg5-Longoral and common blood pressure medications?

A: Regulatory information advises that magnesium, when combined with certain blood pressure medicines like Dihydropyridine calcium channel blockers, may increase the risk of low blood pressure (hypotension). This warning is based on the drug's fundamental activity on vascular tone.


Q: Is it considered normal to see what looks like the empty tablet shell or casing in the stool after taking a long-acting formulation?

A: The extended-release tablet's design often involves a non-digestible casing or matrix to ensure the ingredient is released slowly and continuously. This casing is designed to remain intact as it passes through the body and may sometimes be observed in the stool.


Q: How does the bioavailability of Mg5-Longoral compare to other common magnesium forms, such as magnesium oxide or citrate?

A: Studies indicate that the magnesium aspartate salt used in Mg5-Longoral has a higher rate of absorption compared to inorganic forms like magnesium oxide. The preparation is noted for its high bioavailability, meaning a greater proportion of the magnesium is available for the body to use. Other organic salts like magnesium citrate also exhibit high bioavailability in research.


Q: What is the difference between Mg5-Longoral and a regular over-the-counter magnesium supplement?

A: Mg5-Longoral is a specialized pharmaceutical preparation classified as an electrolyte replacement agent. Unlike many general supplements, this product is intended to treat a documented magnesium deficiency as defined by regulatory and clinical guidelines.


Q: Can the onset of effect vary a lot between different individuals taking Mg5-Longoral?

A: Official research evidence related to supportive effects is marked by heterogeneity across clinical trials and outcomes. This indicates that the individual response, including the time it takes to feel an effect, can be subject to variation between people.


Q: Is Mg5-Longoral considered a fast-acting or a slow-acting medicine in terms of onset?

A: Mg5-Longoral is designed for sustained action rather than a rapid onset. The 'Longoral' system is an extended-release mechanism engineered to ensure the active ingredient is released slowly and continuously over time for prolonged stability.


Q: If a person stops taking Mg5-Longoral, how long does the magnesium content generally stay in the system?

A: Scientific literature estimates that the biologic half-life of magnesium in the body is approximately 42 days, or 1000 hours. This measurement indicates that the elimination of magnesium from the body is a very gradual and slow process.


Q: Is there a way for a patient to verify if Mg5-Longoral is achieving its purpose?

A: Official research uses the serum magnesium concentration, which is determined by a blood test, as the key biomarker. This test is the recognized method to verify that the medicine is successfully maintaining stable magnesium levels in the body.


Q: Does Mg5-Longoral work differently for different health support purposes?

A: No, the mechanism of action is singular and foundational. It involves the basic biological role of the magnesium cation to stabilize and modulate cellular activity. This fundamental effect provides the basis for all its supportive roles in the nervous, muscular, and vascular systems.


Q: What is the probability of a person experiencing side effects with this particular formulation?

A: Regulatory authorities categorize the probability of side effects by frequency. Gastrointestinal issues like soft stools and diarrhea are considered Uncommon, occurring in at least 1 out of every 1,000 patients but fewer than 1 out of 100. Fatigue or tiredness is categorized as Very Rare, occurring in fewer than 1 out of 10,000 patients.


Q: Is it generally safe to take Mg5-Longoral with common over-the-counter pain relievers or antacids?

A: Regulatory information notes a caution regarding co-administration of Mg5-Longoral with other magnesium-containing products, such as certain antacids or laxatives. This combination increases the additive risk of hypermagnesemia (too much magnesium). No specific interaction is documented in regulatory sources for common over-the-counter pain relievers.


Q: Are there any specific dietary items or products that are known to interact with Mg5-Longoral?

A: Yes, the consumption of alcohol is specifically noted in regulatory documents. Alcohol is known to both inhibit the intestinal absorption of magnesium and to promote its excretion by the kidneys.


Q: Can Mg5-Longoral affect the body's absorption rate of other prescription medications?

A: Yes, the interaction profile is specifically structured around Mg5-Longoral reducing the absorption and subsequent efficacy of co-administered medicines. This reduced absorption can lower the effectiveness of other prescription drugs, such as certain antibiotics, iron preparations, and oral bisphosphonates.


Q: Is an interaction described with Mg5-Longoral and other mineral supplements like calcium or iron?

A: Yes, interactions requiring dose separation are documented for Iron preparations and Fluoride to prevent reduced absorption. Magnesium may also impact the absorption and stability of other mineral supplements, such as calcium phosphate, by affecting their concentrations in the bloodstream.


Q: What patient groups were specifically included in the primary clinical trials for Mg5-Longoral?

A: Research has specifically explored the use of the preparation in certain patient populations. This includes individuals with underlying health conditions such as Type 2 Diabetes, those with chronic gastrointestinal issues, and patients who experience deficiency-linked migraine headaches.


Q: Why might a healthcare professional choose to prescribe Mg5-Longoral over a generic magnesium tablet?

A: Official documentation highlights the use of the magnesium aspartate salt for its high bioavailability. Furthermore, the unique extended-release design is engineered to maximize total absorption and maintain stable magnesium levels over a prolonged period, which distinguishes it from standard generic tablets.


Q: Does Mg5-Longoral require a special diet or fluid intake to function as intended?

A: Official administration guidelines state the tablet should be swallowed whole with liquid and is typically instructed to be taken before meals. There is no mention in regulatory documents that a special or restrictive diet is required for the medicine to work as intended.

Advertisements

How should Mg5-Longoral be stored and disposed of?

How to Store and Dispose of Mg5-Longoral?

Mg5-Longoral must be stored according to official labeling to maintain the stability of the magnesium aspartate and the extended-release tablet.


Storage Conditions

The medicine must be kept out of the sight and reach of children.

  • Temperature: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not expose the tablets to freezing or excessive heat.
  • Protection: Keep the container tightly closed and store in a dry place to protect the contents from moisture and light.
  • Expiration: Do not use the medicine after the expiration date printed on the package.

Disposal Instructions

Unused or expired Mg5-Longoral must not be disposed of in household trash or poured into a drain/wastewater.

Dispose of the medicine according to local and national requirements for pharmaceutical waste, which often involves a drug take-back program or returning the product to a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mg5-Longoral found in:

A-Z Index: